Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
L-3 (LLL) to Acquire Implant Sciences' (IMSC) ETD Assets in $117.5M+ Deal
-
L-3 Agrees to Acquire Implant Sciences Explosives Trace Detection Assets
-
Inventergy (INVT) Prices Offering of Common Stock and Warrants for Proceeds of $6M
-
Inventergy Announces Pricing of $6.0 Million Public Offering
-
Alnylam Pharmaceuticals (ALNY) PT Cut to $77 at Chardan
-
Stellar Acquisition III Inc. Announces Closing of Partial Over-Allotment Exercise in Connection With Its Initial Public Offering
-
Chardan Capital Markets Upgrades BCommunication Ltd. (BCOM) to Buy
-
Chardan Capital Markets Starts Novartis (NVS) at Buy
-
M I Acquisitions (MACQ) Prices 5M Unit IPO at $10/Unit
-
M I Acquisitions, Inc. Announces Pricing of $50,000,000 Initial Public Offering
-
Chardan Capital Markets, LLC Expands Equity Research Division With Steve Wardell As A Senior Equity Analyst Covering The Healthcare IT And Digital Health Sectors
-
AveXis (AVXS) Prices 4.25M Common Stock Offering for Proceeds of ~$128M
-
AveXis Announces Pricing of Public Offering of Common Stock
-
AveXis (AVXS) to Offer 4M Shares of Common Stock
-
AveXis Announces Proposed Public Offering of 4,000,000 Shares of Common Stock
-
Stellar Acquisition III Inc. Completes $65,000,000 Initial Public Offering
-
Chardan Capital Markets Starts Caladrius Biosciences (CLBS) at Buy, $6.50 PT
-
Stellar Acquisition III Inc. Announces Pricing of $65,000,000 Initial Public Offering
-
Arrowhead Pharmaceuticals Closes $45 Million Private Offering
-
Check-Cap Ltd. Announces $5.9 Million Financing
-
Notable Analyst Rating Changes 8/4: (CELG) (APO) (CNK) Upgraded; (SGMO) (INOV) (GRMN) Downgraded
-
Chardan Capital Markets Upgrades iPass Inc. (IPAS) to Buy
-
Chardan Capital Markets Starts Sunworks (SUNW) at Buy
-
22nd Century Group (XXII) Enters $5M Registered Direct Offering
-
22nd Century Group Announces $5.0 Million Registered Direct Offering at Market
-
Inventergy Announces Private Placement of $3.0 Million
-
Inventergy Global (INVT) Reports $3M Private Placement
-
PlacementTracker Publishes First Half 2016 PIPE Market League Tables
-
Covata Receives Shareholder Approval for Second and Final Tranche of AU$13.2 Million Private Placement of Common Stock to U.S. and Asia-Pac Sophisticated and Institutional Investors
-
Notable Analyst Rating Changes 7/14: (GSK) (RRC) (SO) Upgraded; (ATW) (BRCD) (INFO) Downgraded
-
Pre-Open Stock Movers 07/14: (SUNW) (CREE) (YUM) (JPM) Higher; (ACHN) (LXU) (SUM) Lower (more...)
-
UPDATE: Chardan Capital Starts Achillion Pharma (ACHN) at Sell; Tough Competition, Lack of Data Pose Challenges
-
MTBC Announces Closing of $1.6 million of Additional Non-convertible Series A Cumulative Redeemable Perpetual Preferred Stock Offering
-
M III Acquisition Corp. Announces Closing Of Initial Public Offering
-
Chardan Capital Markets Starts Akari Therapeutics (AKTX) at Sell
-
Notable Analyst Rating Changes 7/8: (CF) (COF) (GFI) Upgraded; (AINV) (HUM) (ABUS) Downgraded
-
Chardan Capital Markets Downgrades Arbutus Biopharma (ABUS) to Sell
-
M III Acquisition (MIII) Prices 15M Units IPO for Proceeds of $150M
-
M III Acquisition Corp. Announces Pricing of $150 Million Initial Public Offering
-
MTBC Files Prospectus Supplement
-
BioTime, Inc. Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
-
Northwest Biotherapeutics (NWBO) Enters $3.7M Registered Direct Offering
-
NW BIO ANNOUNCES A REGISTERED DIRECT OFFERING OF $3.7 MILLION WITH NEW INSTITUTIONAL INVESTORS
-
Regulus Therapeutics (RGLS) PT Cut to $13.50 at Chardan Capital Following Clinical Hold
-
Chardan Capital Markets Starts NICE Systems Ltd (NICE) at Buy
-
BioTime, Inc. Announces Closing of Public Offering of Common Stock
-
Notable Analyst Rating Changes 6/20: (YELP) (SAVE) (SYMC) Upgraded; (EGRX) (SCTY) (ESRX) Downgraded
-
UPDATE: Chardan Capital Markets Starts ProQR Therapeutics N.V. (PRQR) at Neutral
-
BioTime (BTX) Prices 7.3M Stock Offering at $2.39/Share
-
BioTime, Inc. Announces Pricing of Public Offering of Common Stock

